A study by Zhi and colleagues [104] using mouse models found that treatment with the BRAF inhibitor PLX4032 in combination with anti-PD-1 antibody reversed TGF-β1/SMAD3 facilitated repression of tumor-specific major histocompatibility complex class II, increased CD4 T-cell infiltration, and suppressed tumor growth. The gene discussed is BRAF; the disease is neoplasm.